Efficacy, safety and tolerability of artesunate-mefloquine in the treatment of uncomplicated Plasmodium falciparum malaria in four geographic zones of Nigeria
2008

Effectiveness of Artesunate-Mefloquine for Malaria in Nigeria

Sample size: 446 publication Evidence: high

Author Information

Author(s): Agomo Philip U, Meremikwu Martin M, Watila Ismaila M, Omalu Innocent J, Odey Friday A, Oguche Stephen, Ezeiru Valentine I, Aina Olugbenga O

Primary Institution: Nigerian Institute of Medical Research

Hypothesis

The combination of artesunate and mefloquine is effective, safe, and well-tolerated for treating uncomplicated malaria in Nigeria.

Conclusion

The co-packaged formulation of artesunate and mefloquine is highly efficacious, safe, and well-tolerated for treating uncomplicated P. falciparum malaria in Nigeria.

Supporting Evidence

  • Cure rates were over 90% at day 28 for both treatment groups.
  • Mean parasite clearance times were 40.1 hours for group I and 42.4 hours for group II.
  • No serious adverse events were reported during the study.

Takeaway

This study tested a new malaria treatment and found it works really well and is safe for kids and adults in Nigeria.

Methodology

A multi-centre, open-label trial with a three-day regimen of artesunate and mefloquine, following WHO protocols.

Potential Biases

Potential bias due to lack of blinding and the open-label design.

Limitations

The study did not perform PCR analysis to confirm recrudescence or new infections.

Participant Demographics

Participants included children and adults, with weights ranging from 15 kg to over 30 kg.

Statistical Information

Statistical Significance

p > 0.05

Digital Object Identifier (DOI)

10.1186/1475-2875-7-172

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication